



Dimethyl Sulfoxide 50% (Rimso-50) Intravesical Aqueous Solution

The Issue: Dimethyl sulfoxide (DMSO) 50% intravesical aqueous solution is manufactured by Mylan Pharmaceuticals with no other suppliers available.

Anticipated Availability: Resupply date is being consistently delayed. Current ETA mid-January 2020.

Practice Implications: All stock has expired and resupply has been delayed. Clinicians may need to reschedule treatments or consider other alternatives.

Alternatives*: The Canadian and American Urological Associations indicate treatment of interstitial cystitis must be individualized and they recommend using more conservative therapies first. The following oral medications are considered second line therapeutic alternatives:

- amitriptyline 25 to 75 mg PO qHS
- cimetidine 400 mg PO BID
- hydroxyzine 10 to 50 mg PO qHS

A therapeutic alternative for intravesicular administration that is being recommended by BC Health Authority pharmacies is a heparin/lidocaine/sodium bicarbonate compounded solution. The specific proportions of these medications are:

- heparin 10,000 units/mL x 2 mL, lidocaine 2% x 8 mL and sodium bicarbonate 8.4% x 4 mL. Total volume for administration = 14 mL.

The above solution should be prepared just prior to bladder instillation, using good aseptic procedures. Contact Pharmacy if you have questions on preparation.

December 13, 2019 For the information of physicians, nurses, and pharmacists. PLEASE POST	Drug Shortage	√	For further information contact: <i>Jessica Brecknock *or* Ryan Doerksen</i> Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		
	Best Practice		

*Alternates are provided for clinician information and may not be appropriate for all clinical situations. The information provided does not replace clinical judgment.